Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-17T10:58:54.018Z Has data issue: false hasContentIssue false
  • English
  • Français

New Pharmacotherapeutic Approaches to Obsessive-Compulsive Disorder

Published online by Cambridge University Press:  07 November 2014

Martijn Figee  and
Damiaan Denys
Martijn Figee
Affiliation:
Drs. Figee and Denys are professors in the Department of Psychiatry at the Academic Medical Centre of the, University of Amsterdam.
Get access Rights & Permissions [Opens in a new window]

Abstract

This article summarizes results of all pharmacotherapy trials for obsessive-compulsive disorder (OCD) published from 2006 to 2008 as well as studies on markers for predicting response to treatment and neurobiological changes induced by pharmacotherapy. Results show that recent developments in the treatment of OCD have been modest and primarily involve evidence for the efficacy of escitalopram and other selective serotonin reuptake inhibitors (SSRIs); augmentation with antipsychotics in treatment-refractory patients and combination treatment with D-cycloserine and cognitive-behavioral therapy has also been effective. The efficacy of serotonin-norepinephrine reuptake inhibitors remains inconclusive. Studies on markers of clinical response have shown inconsistent results, however, duration and severity of OCD and the presence of comorbidities can often identify patients at risk for nonresponse. Lastly, successful treatment with an SSRI results in both serotonergic and dopaminergic changes, but more research is necessary in order to define the biological characteristics of responders and nonresponders.

Type
Research Article
Information
CNS Spectrums , Volume 14 , Issue S3 , 2009 , pp. 13 - 23
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.American Psychiatric Association. Treatment of Patients With Obsessive-Compulsive Disorder. Available at: www.psychiatryonline.com/pracGuide/pracGuideChapToc_10.aspx. Accessed January 30, 2009.Google Scholar
2.Denys, D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am. 2006;29(2):553–84, xi.Google Scholar
3.Turner, EH, Matthews, AM, Linardatos, E, Tell, RA, Rosenthal, R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252–260.CrossRefGoogle ScholarPubMed
4.Wilhelm, S, Buhlmann, U, Tolin, DF, et al.Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008;165(3):335–341.Google Scholar
5.Storch, EA, Merlo, LJ, Bengtson, M, et al.D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007;22(4):230–237.Google Scholar
6.Kushner, MG, Kim, SW, Donahue, C, et al.D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry. 2007;62(8):835–838.Google Scholar
7.Stein, DJ, Andersen, EW, Tonnoir, B, Fineberg, N. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007;23(4):701–711.CrossRefGoogle ScholarPubMed
8.Stein, DJ, Andersen, EW, Overo, KF. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. Rev Bras Psiquiatr. 2007;29(4):303–307.CrossRefGoogle ScholarPubMed
9.Fineberg, NA, Tonnoir, B, Lemming, O, Stein, DJ. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2007;17(6-7):430–439.Google Scholar
10.Rabinowitz, I, Baruch, Y, Barak, Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2008;23(1):49–53.Google Scholar
11.Onder, E, Tural, U, Gokbakan, M. Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder? Eur Arch Psychiatry Clin Neurosci. 2008;258(6):319–323.Google Scholar
12.Galvão-de Almeida, A, Quarantini, LC, Góis, CR, et al.Obsessive-compulsive disorder: an open-label pilot trial of escitalopram. CNS Spectr. 2007;12(7):519–524.CrossRefGoogle ScholarPubMed
13.Saxena, S, Brody, AL, Maidment, KM, Baxter, LR Jr.Paroxetine treatment of compulsive hoarding. J Psychiatr Res. 2007;41(6):481–487.Google Scholar
14.Moreno, FA, Wiegand, CB, Taitano, EK, Delgado, PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735–1740.Google Scholar
15.Shim, GS, Kang, DH, Kwon, JS. High-dose escitalopram treatment in patients with obsessive-compulsive disorder: a naturalistic case series. J Clin Psychopharmacol. 2008;28(1):108–110.CrossRefGoogle ScholarPubMed
16.Desarkar, P, Das, A, Nizamie, SH. Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases. J Clin Psychopharmacol. 2007;27(3):305–306.Google Scholar
17.Mouaffak, F, Gallarda, T, Baylé, FJ, Olié, JP, Baup, N. Worsening of obsessive-compulsive symptoms after treatment with aripiprazole. J Clin Psychopharmacol. 2007;27(2):237–238.Google Scholar
18.Soomro, GM, Altman, D, Rajagopal, S, Oakley-Browne, M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;(1):CD001765.Google Scholar
19.Fineberg, NA, Pampaloni, I, Pallanti, S, Ipser, J, Stein, DJ. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007;22(6):313–322.Google Scholar
20.Maina, G, Pessina, E, Albert, U, Bogetto, F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2008;18(5):364–372.Google Scholar
21.Amiaz, R, Fostick, L, Gershon, A, Zohar, J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol. 2008;18(6):455–461.CrossRefGoogle ScholarPubMed
22.Simpson, HB, Foa, EB, Liebowitz, MR, et al.A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry. 2008;165(5):621–630.Google Scholar
23.Van Ameringen, M, Mancini, C, Patterson, B, Bennett, M. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety. 2006;23(1):1–5.Google Scholar
24.Tundo, A, Salvati, L, Busto, G, Di Spigno, D, Falcini, R. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study. J Clin Psychiatry. 2007;68(10):1552–1556.Google Scholar
25.Dell’osso, B, Mundo, E, Marazziti, D, Altamura, AC. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol. 2008;22(2):210–213.Google Scholar
26.Sarkar, R, Klein, J, Kruger, S. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. Psychopharmacology (Berl). 2008;197(4):687–688.Google Scholar
27.Yang, KC, Su, TP, Chou, YH. Effectiveness of aripiprazole in treating obsessive compulsive symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):585–586.CrossRefGoogle ScholarPubMed
28.da Rocha, FF, Correa, H. Successful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1550–1551.Google Scholar
29.Friedman, S, Abdallah, TA, Oumaya, M, Rouillon, F, Guelfi, JD. Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2007;68(6):972–973.Google Scholar
30.Luis, BS, Black, DW. A case of obsessive-compulsive disorder responding to duloxetine. Prim Care Companion J Clin Psychiatry. 2007;9(3):234–235.Google Scholar
31.Denys, D, Fineberg, N, Carey, PD, Stein, DJ. Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry. 2007;61(3):412–414.Google Scholar
32.Fineberg, NA, Gale, TM, Sivakumaran, T. A review of antipsychotics in the treatment of obsessive compulsive disorder. J Psychopharmacol. 2006;20(1):97–103.Google Scholar
33.Bloch, MH, Landeros-Weisenberger, A, Kelmendi, B, Coric, V, Bracken, MB, Leckman, JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622–632.CrossRefGoogle ScholarPubMed
34.Stein, DJ, Ipser, JC, Baldwin, DS, Bandelow, B. Treatment of obsessive-compulsive disorder. CNS Spectr. 2007;12(2 suppl 3):28–35.CrossRefGoogle Scholar
35.Goodman, WK, Price, LH, Rasmussen, SAet al.The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006–1011.Google Scholar
36.Goodman, WK, Price, LH, Rasmussen, SAet al.The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989;46(11):1012–1016.CrossRefGoogle ScholarPubMed
37.Guy, W. Clinical global impressions (CGI) scale. In: Rush, AJ, Pincus, HA, First, MB, et al. eds. Handbook of Psychiatric Measures. 1st ed. Washington, DC: American Psychiatric Association; 2000:100–102.Google Scholar
38.Tolin, DF, Abramowitz, JS, Diefenbach, GJ. Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale. J Clin Psychiatry. 2005;66(12):1549–1557.Google Scholar
39.Sánchez, C, Bøgesø, KP, Ebert, B, Reines, EH, Braestrup, C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl ). 2004;174(2):163–176.Google Scholar
40.Fineberg, NA, Gale, TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2005;8(1):107–129.Google Scholar
41.Denys, D, Van Nieuwerburgh, F, Deforce, D, Westenberg, HG. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry. 2007;68(5):747–753.Google Scholar
42.Goisman, RM, Rogers, MP, Steketee, GS, Warshaw, MG, Cuneo, P, Keller, MB. Utilization of behavioral methods in a multicenter anxiety disorders study. J Clin Psychiatry. 1993;54(6):213–218.Google Scholar
43.Foa, EB, Kozak, MJ, Steketee, GS, McCarthy, PR. Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behaviour therapy. Br J Clin Psychol. 1992;31 (Pt. 3):279–292.Google Scholar
44.Franklin, ME, Abramowitz, JS, Kozak, MJ, Levitt, JT, Foa, EB. Effectiveness of exposure and ritual prevention for obsessive-compulsive disorder: randomized compared with nonrandomized samples. J Consult Clin Psychol. 2000;68(4):594–602.Google Scholar
45.Baldwin, DS, Anderson, IM, Nutt, DJ, et al.Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19(6):567–596.Google Scholar
46.Koran, LM, Hanna, GL, Hollander, E, Nestadt, G, Simpson, HB, and the American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164(7 suppl):5–53.Google Scholar
47.Hewlett, WA, Schmid, SP, Salomon, RM. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003;64(9):1025–1030.CrossRefGoogle ScholarPubMed
48.Lundberg, S, Carlsson, A, Norfeldt, P, Carlsson, ML. Nicotine treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(7):1195–1199.Google Scholar
49.Pasquini, M, Garavini, A, Biondi, M. Nicotine augmentation for refractory obsessive-compulsive disorder. A case report. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(1):157–159.CrossRefGoogle ScholarPubMed
50.Taylor, LH, Kobak, KA. An open-label trial of St. John’s Wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry. 2000;61(8):575–578.Google Scholar
51.Strassman, RJ, Qualls, CR, Uhlenhuth, EH, Kellner, R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994;51(2):98–108.Google Scholar
52.Pallanti, S, Hollander, E, Bienstock, C, et al.Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 2002;5(2):181–191.Google Scholar
53.Ipser, JC, Carey, P, Dhansay, Y, Fakier, N, Seedat, S, Stein, DJ. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006;(4):CD005473.Google Scholar
54.Kordon, A, Wahl, K, Koch, N, et al.Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2008;28(5):550–554.Google Scholar
55.Connor, KM, Payne, VM, Gadde, KM, Zhang, W, Davidson, JR. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005;66(1):49–51.Google Scholar
56.Fineberg, NA, Stein, DJ, Premkumar, P, et al.Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol. 2006;21(6):337–343.Google Scholar
57.Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.Google Scholar
58.Hamilton, M. Hamilton anxiety rating scale (HARS). In: Rush, AJ, Pincus, HA, First, MB, et al. eds. Handbook of Psychiatric Measures. 1st ed. Washington, DC: American Psychiatric Association; 2000:554–557.Google Scholar
59.Insel, TR, Pickar, D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am J Psychiatry. 1983;140(9):1219–1220.Google Scholar
60.Coric, V, Milanovic, S, Wasylink, S, Patel, P, Malison, R, Krystal, JH. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl). 2003;167(2):219–220.Google Scholar
61.Eddy, KT, Dutra, L, Bradley, R, Westen, D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004;24(8):1011–1030.Google Scholar
62.Foa, EB, Liebowitz, MR, Kozak, MJ, et al.Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162(1):151–161.Google Scholar
63.Walker, DL, Ressler, KJ, Lu, KT, Davis, M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002;22(6):2343–2351.Google Scholar
64.Richardson, R, Ledgerwood, L, Cranney, J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn Mem. 2004;11(5):510–516.Google Scholar
65.Woods, AM, Bouton, ME. D-cycloserine facilitates extinction but does not eliminate renewal of the conditioned emotional response. Behav Neurosci. 2006;120(5):1159–1162.CrossRefGoogle Scholar
66.Ressler, KJ, Rothbaum, BO, Tannenbaum, L, et al.Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61(11):1136–1144.Google Scholar
67.Hofmann, SG, Meuret, AE, Smits, JA, et al.Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63(3):298–304.Google Scholar
68.Norberg, MM, Krystal, JH, Tolin, DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63(12):1118–1126.Google Scholar
69.Quartermain, D, Mower, J, Rafferty, MF, Herting, RL, Lanthorn, TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol. 1994;257(1-2):7–12.Google Scholar
70.Hamilton, M. Hamilton rating scale for depression (HAM-D). In: Rush, AJ, Pincus, HA, First, MB, et al. eds. Handbook of Psychiatric Measures. 1st ed. Washington, DC: American Psychiatric Association; 2000:526–529.Google Scholar
71.Baxter, LR Jr, Schwartz, JM, Bergman, KS, et al.Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry. 1992;49(9):681–689.CrossRefGoogle ScholarPubMed
72.Sumitani, S, Harada, M, Kubo, H, Ohmori, T. Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive-compulsive disorder patients. Psychiatry Res. 2007;154(1):85–92.CrossRefGoogle ScholarPubMed
73.Barker, PB. N-acetyl aspartate--a neuronal marker? Ann Neurol. 2001;49(4):423–424.Google Scholar
74.Ebert, D, Speck, O, Konig, A, Berger, M, Hennig, J, Hohagen, F. 1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: evidence for neuronal loss in the cingulate gyrus and the right striatum. Psychiatry Res. 1997;74(3):173–176.Google Scholar
75.Rosenberg, DR, MacMaster, FP, Keshavan, MS, Fitzgerald, KD, Stewart, CM, Moore, GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry. 2000;39(9):1096–1103.Google Scholar
76.Hurley, RA, Saxena, S, Rauch, SL, Hoehn-Saric, R, Taber, KH. Predicting treatment response in obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 2002;14(3):249–253.CrossRefGoogle ScholarPubMed
77.Moresco, RM, Pietra, L, Henin, M, et al.Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naive patients. Neuropsychopharmacology. 2007;32(1):197–205.Google Scholar
78.Kim, CH, Cheon, KA, Koo, MS, et al.Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors. Neuropsychobiology. 2007;55(3-4):156–162.Google Scholar
79.Pogarell, O, Poepperl, G, Mulert, C, et al.SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD). Eur Neuropsychopharmacol. 2005;15(5):521–524.Google Scholar
80.Zitterl, W, Aigner, M, Stompe, T, et al.Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology. 2008;33(13):3126–3134.Google Scholar